Tesamorelin Food and Supplement Interactions: What Was Tested

The Label Asks for Named-Drug Monitoring

The current EGRIFTA WR prescribing information says:

“Monitor patients for potential interactions when administering EGRIFTA WR in combination with other drugs known to be metabolized by CYP450 liver enzymes.”

The issuer is FDA through the approved label. This sentence is a medicine-interaction precaution; it does not classify every CYP substrate, food, or supplement as unsafe and does not endorse EGRIFTA or HealthRX.com (label section 7.1).

That wording is more useful than a generic avoid-list because it keeps the question attached to a named co-medication, its therapeutic range, and the available evidence.

The Interaction Evidence Map

What the Two Direct PK Studies Establish

Two randomized crossover studies in healthy volunteers examined a 2 mg earlier EGRIFTA formulation with simvastatin or ritonavir. Simvastatin exposure measures stayed within the usual no-effect range; ritonavir showed small exposure decreases, with the authors concluding that tesamorelin's impact on CYP3A appeared minimal in those study settings (PMID 27121785; DOI 10.1002/cpdd.27).

That evidence is specific to two named medicines, doses, populations, and designs. It cannot be stretched to statins as a class, all antiretrovirals, narrow-therapeutic-index drugs, or botanical CYP claims.

The label separately warns that growth hormone can affect CYP450-mediated clearance and that people receiving glucocorticoid replacement for diagnosed hypoadrenalism may require clinician-managed changes. Cortisone acetate and prednisone may be more affected because they depend on conversion to active metabolites (EGRIFTA WR sections 7.1–7.2).

Why Food Physiology Does Not Create an Injection Schedule

Tesamorelin is administered subcutaneously. Food can still matter to glucose, nutrition, symptoms, alcohol exposure, or absorption of a separate oral medicine, but it does not pass through the same absorption pathway as the injection.

The legacy page converted general growth-hormone physiology into a fasting preference, high-sugar avoidance, alcohol timing, protein targets, and supplement warnings. No direct tesamorelin comparison validated those rules.

MedlinePlus instead gives a practical disclosure instruction: tell the prescriber and pharmacist about prescription medicines, nonprescription medicines, vitamins, nutritional supplements, and herbal products (NLM tesamorelin monograph). Disclosure is not proof of an interaction; it makes a named assessment possible.

The drug–drug interaction overview organizes label-supported medicine questions. The levothyroxine interaction audit shows why mechanism is not a measured dose adjustment, and the overdose triage record explains why exact product and coexposure details matter after an error.

The Responsible Bottom Line

The evidence supports a named-interaction map, not a universal diet or supplement chart. The label supplies no fasting requirement, and the direct PK literature answers two medicine questions. Every additional product needs its own identity, purpose, exposure, and evidence review.

Medical review of this revision is pending. FDA, NLM, sponsors, investigators, institutions, journals, and authors do not endorse tesamorelin, HealthRX.com, or this page.